Post-traumatic stress disorder

Summary

Post-traumatic stress disorder (MONDO:0005146) is a disease with 35 cohort genes (516 GWAS associations across 40 studies) and 1,399 clinical trials. The dominant Reactome pathway is Regulation of insulin secretion (3 cohort genes). Top therapeutic interventions include prazosin, paroxetine, and propranolol.

At a glance

• Cohort genes: 35
• GWAS associations: 516
• ClinVar variants: 3
• Clinical trials: 1,399

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	post-traumatic stress disorder
Mondo ID	MONDO:0005146
EFO	EFO:0001358
MeSH	D013313
DOID	DOID:2055
ICD-10-CM	F43.1
NCIT	C3389
SNOMED CT	47505003
UMLS	C0038436
MedGen	21345
Is cancer (heuristic)	no

Also known as: combat neurosis · post-traumatic stress disorder · PTSD · traumatic neurosis

Data availability: 3 ClinVar variants · 516 GWAS associations (40 studies).

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › neurotic disorder › post-traumatic stress disorder

Genetics & variants

GWAS landscape

516 GWAS associations across 40 studies. Top hits map to 21 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1476535	4e-20	FOXP2	T	9.18
rs62056789	1e-19	MAPT, MAPT-IT1	A	0.02
rs6759922	1e-18	LINC01830	A	8.82
rs488769	1e-18	ZDHHC5	A	8.81
rs10865093	9e-18	LINC01830	T	8.59
rs2186710	3e-17	LINC02763 - NCAM1-AS2	C	8.46
rs59145082	2e-16	LINC01830	?
rs7106434	4e-16	NCAM1	T	8.12
rs10789373	8e-16	LINC01360 - LINC02238	C	8.06
rs12128161	2e-15	LINC01360 - LINC02238	A	7.95
rs7431106	2e-15	IP6K1	A	7.94
rs11210146	4e-15	KRT8P21 - RN7SKP19	?
rs11130221	7e-15	IP6K1	C	7.79
rs1355178	1e-14	LINC01830	?
rs5015511	4e-14	LINC01830	?
rs28986300	8e-14	GABBR1	A	7.47
rs29242	8e-14	GABBR1	T	7.46
chr2:104454345	3e-13		A	0.04
rs9479138	3e-13	ESR1	T	7.28
rs7797335	3e-13	FOXP2	?
chr11:28630051	4e-13		A	0.04
rs10821163	4e-13	PHF2	C	7.25
rs2135029	4e-13	SGCD	A	7.25
rs7523829	6e-13	RN7SKP19 - LINC01360	?
rs10235664	7e-13	MAD1L1	T	0.02
rs10992779	1e-12	FAM120A	A	7.13
rs4632195	2e-12	DCC	T	7.06
rs10229691	2e-12	FOXP2	?
rs139582054	2e-12	GPX5 - SCAND3	?
rs10992729	3e-12	Y_RNA - FAM120AOS	T	0.01

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90627735	Nievergelt CM	2024	137,136	1,085,746	Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder.
GCST90627736	Nievergelt CM	2024	137,136	1,085,746	Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder.
GCST90476515	Verma A	2024	102,584	332,738	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90271338	Gong W	2023	54,854	552,920	Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis.
GCST90271326	Gong W	2023	53,400	584,648	Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis.
GCST90480755	Verma A	2024	40,334	75,108	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481787	Verma A	2024	40,334	75,108	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90271773	Stein MB	2021	36,301	178,107	Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program.
GCST90271775	Stein MB	2021	36,301	178,107	Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program.
GCST90455649	Chen D	2024	23,212	151,447	Unraveling shared susceptibility loci and Mendelian genetic associations linking educational attainment with multiple neuropsychiatric disorders.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	50

MAF distribution

Bucket	Variants
common (>=0.05)	50
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	34
intergenic_variant	12
unknown	3
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1476535	7	114430980	C>A,G,T	0.424	intron_variant	FOXP2	4e-20	Tier 4: intronic/intergenic
rs62056789	17	45898049	A>C,T	0.05	non_coding_transcript_exon_variant	MAPT, MAPT-IT1	1e-19	Tier 4: intronic/intergenic
rs6759922	2	22227377	G>A,T	0.457	intron_variant	LINC01830	1e-18	Tier 4: intronic/intergenic
rs488769	11	57683248	A>C,T	0.344	intron_variant	ZDHHC5	1e-18	Tier 4: intronic/intergenic
rs10865093	2	22236500	T>C	0.455	intron_variant	LINC01830	9e-18	Tier 4: intronic/intergenic
rs2186710	11	112956325	C>A,G,T	0.455	intergenic_variant	LINC02763 - NCAM1-AS2	3e-17	Tier 4: intronic/intergenic
rs59145082	2	22312386	A>G,T	0.05	intron_variant	LINC01830	2e-16	Tier 4: intronic/intergenic
rs7106434	11	112989857	T>C	0.462	intron_variant	NCAM1	4e-16	Tier 4: intronic/intergenic
rs10789373	1	73500186	G>A,C,T	0.394	intergenic_variant	LINC01360 - LINC02238	8e-16	Tier 4: intronic/intergenic
rs12128161	1	73371734	C>A,G	0.392	intron_variant	LINC01360 - LINC02238	2e-15	Tier 4: intronic/intergenic
rs7431106	3	49770941	G>A	0.491	intron_variant	IP6K1	2e-15	Tier 4: intronic/intergenic
rs11210146	1	73156324	A>C,G,T	0.05	intergenic_variant	KRT8P21 - RN7SKP19	4e-15	Tier 4: intronic/intergenic
rs11130221	3	49781669	C>G,T	0.489	intron_variant	IP6K1	7e-15	Tier 4: intronic/intergenic
rs1355178	2	22365653	T>A,G	0.05	intron_variant	LINC01830	1e-14	Tier 4: intronic/intergenic
rs5015511	2	22323980	G>A,T	0.05	intron_variant	LINC01830	4e-14	Tier 4: intronic/intergenic
rs28986300	6	29583119	A>G	0.064	intron_variant	GABBR1	8e-14	Tier 4: intronic/intergenic
rs29242	6	29631092	T>C,G	0.054	intron_variant	GABBR1	8e-14	Tier 4: intronic/intergenic
chr2:104454345				0.462			3e-13	Tier 4: intronic/intergenic
rs9479138	6	151894064	T>A,G	0.372	intron_variant	ESR1	3e-13	Tier 4: intronic/intergenic
rs7797335	7	114564074	T>A,C,G	0.05	intron_variant	FOXP2	3e-13	Tier 4: intronic/intergenic
chr11:28630051				0.377			4e-13	Tier 4: intronic/intergenic
rs10821163	9	93580778	G>A,C,T	0.339	intron_variant	PHF2	4e-13	Tier 4: intronic/intergenic
rs2135029	5	156429528	G>A,T	0.394	intron_variant	SGCD	4e-13	Tier 4: intronic/intergenic
rs7523829	1	73292434	G>A	0.05	intergenic_variant	RN7SKP19 - LINC01360	6e-13	Tier 4: intronic/intergenic
rs10235664	7	2047179	T>C	0.05	intron_variant	MAD1L1	7e-13	Tier 4: intronic/intergenic
rs10992779	9	93542374	A>G	0.339	intron_variant	FAM120A	1e-12	Tier 4: intronic/intergenic
rs4632195	18	53220378	C>G,T	0.476	intron_variant	DCC	2e-12	Tier 4: intronic/intergenic
rs10229691	7	114384124	G>A	0.05	intron_variant	FOXP2	2e-12	Tier 4: intronic/intergenic
rs139582054	6	28567056	C>G,T	0.05	intergenic_variant	GPX5 - SCAND3	2e-12	Tier 4: intronic/intergenic
rs10992729	9	93418793	C>A,G,T	0.05	intergenic_variant	Y_RNA - FAM120AOS	3e-12	Tier 4: intronic/intergenic

ClinVar germline variants

3 retrieved; paginated sample, class counts are floors:

2 likely risk allele, 1 uncertain risk allele

ClinVar	Variant (HGVS)	Gene	Classification	Review
3024130	NM_001709.5(BDNF):c.[*1785G>T;-21-14109C>G196G>A]		Likely risk allele	no assertion criteria provided
1722519	NM_000719.7(CACNA1C):c.477+115699G>A	CACNA1C	Uncertain risk allele	no assertion criteria provided
1712509	NM_004117.4(FKBP5):c.106-2636A>G	FKBP5	Likely risk allele	no assertion criteria provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 26 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RPS29	Orphanet:124	Diamond-Blackfan anemia
SLC4A4	Orphanet:93607	Autosomal recessive proximal renal tubular acidosis
TLL1	Orphanet:99103	Atrial septal defect, ostium secundum type
TLL1	Orphanet:99106	Atrial septal defect, ostium primum type
TRPS1	Orphanet:502	Trichorhinophalangeal syndrome type 2
TRPS1	Orphanet:77258	Trichorhinophalangeal syndrome type 1
CACNA1C	Orphanet:101016	Romano-Ward syndrome
CACNA1C	Orphanet:130	Brugada syndrome
CACNA1C	Orphanet:528084	Non-specific syndromic intellectual disability
CACNA1C	Orphanet:595098	Timothy syndrome type 1
CACNA1C	Orphanet:595105	Timothy syndrome type 2
CACNA1C	Orphanet:595109	Atypical Timothy syndrome
ANKRD55	Orphanet:85408	Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis
ANKRD55	Orphanet:85410	Oligoarticular juvenile idiopathic arthritis
TECRL	Orphanet:3286	Catecholaminergic polymorphic ventricular tachycardia
DPP6	Orphanet:228140	Idiopathic ventricular fibrillation
DPP6	Orphanet:2514	Autosomal dominant primary microcephaly
AKT3	Orphanet:83473	Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome
AKT3	Orphanet:99802	Hemimegalencephaly
GABBR2	Orphanet:3095	Atypical Rett syndrome
GABBR2	Orphanet:442835	Non-specific early-onset epileptic encephalopathy
GRIN1	Orphanet:178469	Autosomal dominant non-syndromic intellectual disability
GRIN1	Orphanet:1934	Early infantile developmental and epileptic encephalopathy
GRIN1	Orphanet:208447	Bilateral generalized polymicrogyria
GRIN1	Orphanet:88616	Autosomal recessive non-syndromic intellectual disability
NDRG1	Orphanet:99950	Charcot-Marie-Tooth disease type 4D

Cohort genes → proteins

35 cohort genes, 33 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	33
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RPS29	HGNC:10419	ENSG00000213741	P62273	Small ribosomal subunit protein uS14	gwas
SDC2	HGNC:10659	ENSG00000169439	P34741	Syndecan-2	gwas
SLC4A4	HGNC:11030	ENSG00000080493	Q9Y6R1	Electrogenic sodium bicarbonate cotransporter 1	gwas
TLL1	HGNC:11843	ENSG00000038295	O43897	Tolloid-like protein 1	gwas
TRPS1	HGNC:12340	ENSG00000104447	Q9UHF7	Zinc finger transcription factor Trps1	gwas
PTPRVP	HGNC:13421	ENSG00000243323		protein tyrosine phosphatase receptor type V, pseudogene	gwas
CACNA1C	HGNC:1390	ENSG00000151067	Q13936	Voltage-dependent L-type calcium channel subunit alpha-1C	clinvar
CSMD1	HGNC:14026	ENSG00000183117	Q96PZ7	CUB and sushi domain-containing protein 1	gwas
UST	HGNC:17223	ENSG00000111962	Q9Y2C2	Uronyl 2-sulfotransferase	gwas
TBC1D2	HGNC:18026	ENSG00000095383	Q9BYX2	TBC1 domain family member 2A	gwas
POGK	HGNC:18800	ENSG00000143157	Q9P215	Pogo transposable element with KRAB domain	gwas
LGR6	HGNC:19719	ENSG00000133067	Q9HBX8	Leucine-rich repeat-containing G-protein coupled receptor 6	gwas
COBL	HGNC:22199	ENSG00000106078	O75128	Protein cordon-bleu	gwas
UNC13C	HGNC:23149	ENSG00000137766	Q8NB66	Protein unc-13 homolog C	gwas
PRTFDC1	HGNC:23333	ENSG00000099256	Q9NRG1	Phosphoribosyltransferase domain-containing protein 1	gwas
SIPA1L2	HGNC:23800	ENSG00000116991	Q9P2F8	Signal-induced proliferation-associated 1-like protein 2	gwas
ADCY8	HGNC:239	ENSG00000155897	P40145	Adenylate cyclase type 8	gwas
CYRIB	HGNC:25216	ENSG00000153310	Q9NUQ9	CYFIP-related Rac1 interactor B	gwas
MEX3B	HGNC:25297	ENSG00000183496	Q6ZN04	RNA-binding protein MEX3B	gwas
ANKRD55	HGNC:25681	ENSG00000164512	Q3KP44	Ankyrin repeat domain-containing protein 55	gwas
TRMT9B	HGNC:26725	ENSG00000250305	Q9P272	Probable tRNA methyltransferase 9B	gwas
TECRL	HGNC:27365	ENSG00000205678	Q5HYJ1	Trans-2,3-enoyl-CoA reductase-like	gwas
ZMAT3	HGNC:29983	ENSG00000172667	Q9HA38	Zinc finger matrin-type protein 3	gwas
DPP6	HGNC:3010	ENSG00000130226	P42658	A-type potassium channel modulatory protein DPP6	gwas
MTRNR2L5	HGNC:37162		P0CJ72	Humanin-like 5	gwas
FKBP5	HGNC:3721	ENSG00000096060	Q13451	Peptidyl-prolyl cis-trans isomerase FKBP5	clinvar
MIR3166	HGNC:38386	ENSG00000266581		microRNA 3166	gwas
AKT3	HGNC:393	ENSG00000117020	Q9Y243	RAC-gamma serine/threonine-protein kinase	gwas
GABBR2	HGNC:4507	ENSG00000136928	O75899	Gamma-aminobutyric acid type B receptor subunit 2	gwas
GRIN1	HGNC:4584	ENSG00000176884	Q05586	Glutamate receptor ionotropic, NMDA 1	gwas
LHX2	HGNC:6594	ENSG00000106689	P50458	LIM/homeobox protein Lhx2	gwas
NDRG1	HGNC:7679	ENSG00000104419	Q92597	Protein NDRG1	gwas
OTOR	HGNC:8517	ENSG00000125879	Q9NRC9	Otoraplin	gwas
KAT2B	HGNC:8638	ENSG00000114166	Q92831	Histone acetyltransferase KAT2B	gwas
PRKCA	HGNC:9393	ENSG00000154229	P17252	Protein kinase C alpha type	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RPS29	Small ribosomal subunit protein uS14	Component of the small ribosomal subunit.
SDC2	Syndecan-2	Cell surface proteoglycan which regulates dendritic arbor morphogenesis.
SLC4A4	Electrogenic sodium bicarbonate cotransporter 1	Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3.
TLL1	Tolloid-like protein 1	Protease which processes procollagen C-propeptides, such as chordin, pro-biglycan and pro-lysyl oxidase.
TRPS1	Zinc finger transcription factor Trps1	Transcriptional repressor.
CACNA1C	Voltage-dependent L-type calcium channel subunit alpha-1C	Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents.
CSMD1	CUB and sushi domain-containing protein 1	Potential suppressor of squamous cell carcinomas.
UST	Uronyl 2-sulfotransferase	Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to the 2-OH position of uronyl residues in glycosaminoglycan chains.
TBC1D2	TBC1 domain family member 2A	Acts as a GTPase-activating protein for RAB7A.
LGR6	Leucine-rich repeat-containing G-protein coupled receptor 6	Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a marker of multipotent stem cells in the epidermis.
COBL	Protein cordon-bleu	Plays an important role in the reorganization of the actin cytoskeleton.
UNC13C	Protein unc-13 homolog C	May play a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway.
PRTFDC1	Phosphoribosyltransferase domain-containing protein 1	Has low, barely detectable phosphoribosyltransferase activity (in vitro).
ADCY8	Adenylate cyclase type 8	Catalyzes the formation of cAMP in response to calcium entry leadings to cAMP signaling activation that affect processes suche as synaptic plasticity and insulin secretion.
CYRIB	CYFIP-related Rac1 interactor B	Negatively regulates RAC1 signaling and RAC1-driven cytoskeletal remodeling.
MEX3B	RNA-binding protein MEX3B	RNA-binding protein.
TRMT9B	Probable tRNA methyltransferase 9B	May modify wobble uridines in specific arginine and glutamic acid tRNAs.
ZMAT3	Zinc finger matrin-type protein 3	Acts as a bona fide target gene of p53/TP53.
DPP6	A-type potassium channel modulatory protein DPP6	Promotes cell surface expression of the potassium channel KCND2.
MTRNR2L5	Humanin-like 5	Plays a role as a neuroprotective and antiapoptotic factor.
FKBP5	Peptidyl-prolyl cis-trans isomerase FKBP5	Immunophilin protein with PPIase and co-chaperone activities.
AKT3	RAC-gamma serine/threonine-protein kinase	AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis.
GABBR2	Gamma-aminobutyric acid type B receptor subunit 2	Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2.
GRIN1	Glutamate receptor ionotropic, NMDA 1	Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+).
LHX2	LIM/homeobox protein Lhx2	Acts as a transcriptional activator.
NDRG1	Protein NDRG1	Stress-responsive protein involved in hormone responses, cell growth, and differentiation.
KAT2B	Histone acetyltransferase KAT2B	Functions as a histone acetyltransferase (HAT) to promote transcriptional activation.
PRKCA	Protein kinase C alpha type	Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenes…

Protein-family classification

Druggable: 9 · Difficult: 9 · Unknown: 17 · Druggable fraction: 0.26

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Complement	1	7.7×	0.557
Ion channel	1	3.2×	0.557
Protease	2	2.1×	0.557
Scaffold/PPI	4	2.0×	0.557
Kinase	2	1.6×	0.557
GPCR	2	1.4×	0.557
Transcription factor	5	1.2×	0.557
Other/Unknown	17	0.9×	0.953
Enzyme (other)	1	0.3×	0.953

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RPS29	Other/Unknown	no		Ribosomal_uS14, Ribosomal_uS14_CS, RIbosomal_uS14_euk_arc
SDC2	Other/Unknown	no		Syndecan, Neurexin-like, Syndecan/Neurexin_dom
SLC4A4	Other/Unknown	no		HCO3_transpt_euk, Na/HCO3_transpt, HCO3_transpt-like_TM_dom
TLL1	Protease	yes		EGF-type_Asp/Asn_hydroxyl_site, EGF, CUB_dom
TRPS1	Transcription factor	no		Znf_GATA, Znf_C2H2_type, Znf_NHR/GATA
PTPRVP	Other/Unknown	no
CACNA1C	Ion channel	yes		VDCCAlpha1, VDCC_L_a1su, VDCC_L_a1csu
CSMD1	Complement	yes		Sushi_SCR_CCP_dom, CUB_dom, Sperma_CUB_dom_sf
UST	Other/Unknown	no		Sulfotransferase, Heparan_SO4_2-O-STrfase, P-loop_NTPase
TBC1D2	Scaffold/PPI	no		Rab-GAP-TBC_dom, PH_domain, PH-like_dom_sf
POGK	Transcription factor	no		KRAB, aKRAB, DDE_SF_endonuclease_dom
LGR6	GPCR	yes		GPCR_Rhodpsn, LRRNT, Leu-rich_rpt
COBL	Other/Unknown	no		WH2_dom, Cordon-bleu_ubiquitin_domain, COBL-like
UNC13C	Other/Unknown	no		C2_dom, PKC_DAG/PE, MUN_dom
PRTFDC1	Other/Unknown	no		PRTase_dom, Hxn_phspho_trans, PRTase-like
SIPA1L2	Scaffold/PPI	no		Rap/Ran_GAP_dom, PDZ, SIPA1L_C
ADCY8	Other/Unknown	no		A/G_cyclase, Adcy_conserved_dom, A/G_cyclase_CS
CYRIB	Other/Unknown	no		CYRIA/CYRIB_Rac1-bd, CYRI
MEX3B	Transcription factor	no		Znf_RING, KH_dom, KH_dom_type_1
ANKRD55	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf
TRMT9B	Other/Unknown	no		Methyltransf_11, SAM-dependent_MTases_sf, AlkB_tRNA_MeTrf/Diox
TECRL	Other/Unknown	no		3-oxo-5_a-steroid_4-DH_C, SRD5A/TECR, TECRL_Ubl
ZMAT3	Transcription factor	no		Matrin/U1-like-C_Znf_C2H2, Znf_C2H2_type, Znf_C2H2_jaz
DPP6	Protease	yes		Peptidase_S9_cat, Peptidase_S9B_N, AB_hydrolase_fold
MTRNR2L5	Other/Unknown	no		Humanin
FKBP5	Other/Unknown	no		PPIase_FKBP_dom, TPR-like_helical_dom_sf, TPR_rpt
MIR3166	Other/Unknown	no
AKT3	Kinase	yes	2.7.11.1	Prot_kinase_dom, AGC-kinase_C, PH_domain
GABBR2	GPCR	yes		GPCR_3, ANF_lig-bd_rcpt, GPCR3_GABA-B
GRIN1	Other/Unknown	no		Iontro_rcpt_C, Iono_Glu_rcpt_met, ANF_lig-bd_rcpt
LHX2	Transcription factor	no		HD, Znf_LIM, Homeodomain-like_sf
NDRG1	Other/Unknown	no		NDRG, AB_hydrolase_fold
OTOR	Scaffold/PPI	no		SH3_domain, Otoraplin_SH3, SH3-like_dom_sf
KAT2B	Enzyme (other)	yes	2.3.1.48	GNAT_dom, Bromodomain, PCAF_N
PRKCA	Kinase	yes	2.7.11.13	C2_dom, Prot_kinase_dom, AGC-kinase_C

Expression context

Cohort genes with no expression data: 1.

31 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	34
unknown	1

Top tissues across cohort

Tissue	Cohort genes
calcaneal tendon	4
lateral globus pallidus	4
Brodmann (1909) area 23	4
ganglionic eminence	4
middle temporal gyrus	3
caput epididymis	2
buccal mucosa cell	2
primordial germ cell in gonad	2
secondary oocyte	2
right testis	2
right coronary artery	2
pons	2
monocyte	2
mononuclear cell	2
cortical plate	2
endothelial cell	2
ventricular zone	2
left ventricle myocardium	2
lateral nuclear group of thalamus	2
sperm	2

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RPS29	295	ubiquitous	marker	caput epididymis, penis, parietal pleura
SDC2	290	ubiquitous	marker	tibia, calcaneal tendon, synovial joint
SLC4A4	268	ubiquitous	marker	jejunal mucosa, lateral globus pallidus, mucosa of sigmoid colon
TLL1	162	broad	marker	secondary oocyte, buccal mucosa cell, primordial germ cell in gonad
TRPS1	284	ubiquitous	marker	mammary duct, epithelium of mammary gland, calcaneal tendon
PTPRVP	124		marker	right testis, left testis, testis
CACNA1C	134	broad	marker	apex of heart, right coronary artery, muscle layer of sigmoid colon
CSMD1	179	broad	marker	Brodmann (1909) area 23, middle temporal gyrus, primary visual cortex
UST	261	ubiquitous	marker	pons, calcaneal tendon, adrenal tissue
TBC1D2	243	ubiquitous	marker	monocyte, upper lobe of left lung, mononuclear cell
POGK	274	ubiquitous	marker	Brodmann (1909) area 46, cortical plate, ganglionic eminence
LGR6	201	broad	marker	right coronary artery, descending thoracic aorta, thoracic aorta
COBL	255	broad	marker	inferior vagus X ganglion, parotid gland, lateral globus pallidus
UNC13C	174	broad	marker	secondary oocyte, oocyte, endothelial cell
PRTFDC1	240	ubiquitous	marker	corpus callosum, ventricular zone, ganglionic eminence
SIPA1L2	254	ubiquitous	marker	left ventricle myocardium, cardiac muscle of right atrium, pons
ADCY8	125	ubiquitous	marker	lateral nuclear group of thalamus, dorsal motor nucleus of vagus nerve, caput epididymis
CYRIB	286	ubiquitous	marker	monocyte, mononuclear cell, leukocyte
MEX3B	161	ubiquitous	yes	sperm, ganglionic eminence, right testis
ANKRD55	169	broad	marker	male germ line stem cell (sensu Vertebrata) in testis, sperm, primordial germ cell in gonad
TRMT9B	226	broad	marker	cerebellar vermis, cerebellar cortex, cerebellar hemisphere
TECRL	135	tissue_specific	yes	myocardium, heart right ventricle, left ventricle myocardium
ZMAT3	277	ubiquitous	marker	postcentral gyrus, Brodmann (1909) area 23, parietal lobe
DPP6	221	broad	marker	middle temporal gyrus, Brodmann (1909) area 23, endothelial cell
MTRNR2L5
FKBP5	275	ubiquitous	marker	mucosa of stomach, pericardium, skeletal muscle tissue of biceps brachii
MIR3166	25		yes	blood, gastrocnemius, lower esophagus muscularis layer
AKT3	231	ubiquitous	marker	cortical plate, calcaneal tendon, embryo
GABBR2	193	broad	marker	Brodmann (1909) area 23, lateral nuclear group of thalamus, middle temporal gyrus
GRIN1	215	tissue_specific	marker	right hemisphere of cerebellum, right frontal lobe, cerebellar hemisphere

Protein interactions among cohort

Intra-cohort edges: 8.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
FKBP5	4,900
PRKCA	4,530
KAT2B	4,410
AKT3	3,392
CACNA1C	3,145
NDRG1	2,778
TRPS1	2,588
ADCY8	2,527
LHX2	2,347
DPP6	2,224

Intra-cohort edges

A	B	Sources
ADCY8	CACNA1C	intact
ADCY8	PRKCA	string_interaction
AKT3	FKBP5	biogrid_interaction
ANKRD55	PRTFDC1	string_interaction
CACNA1C	CSMD1	string_interaction
CACNA1C	SLC4A4	intact
COBL	PRTFDC1	string_interaction
PRTFDC1	TLL1	string_interaction

Structural data

PDB: 19 · AlphaFold-only: 14 · No structure: 2

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
RPS29	P62273	200
FKBP5	Q13451	138
GRIN1	Q05586	85
CACNA1C	Q13936	33
GABBR2	O75899	26
KAT2B	Q92831	25
DPP6	P42658	8
PRKCA	P17252	6
MEX3B	Q6ZN04	2
AKT3	Q9Y243	2
SDC2	P34741	1
SLC4A4	Q9Y6R1	1
TLL1	O43897	1
CSMD1	Q96PZ7	1
TBC1D2	Q9BYX2	1
COBL	O75128	1
PRTFDC1	Q9NRG1	1
CYRIB	Q9NUQ9	1
NDRG1	Q92597	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
OTOR	Q9NRC9	89.09
TECRL	Q5HYJ1	84.32
UST	Q9Y2C2	79.64
LGR6	Q9HBX8	77.94
ADCY8	P40145	71.82
ZMAT3	Q9HA38	69.64
MTRNR2L5	P0CJ72	69.13
POGK	Q9P215	68.59
LHX2	P50458	67.03
ANKRD55	Q3KP44	63.43
TRMT9B	Q9P272	62.21
UNC13C	Q8NB66	61.64
SIPA1L2	Q9P2F8	56.59
TRPS1	Q9UHF7	49.12

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 326. Enrichment computed across 35 evidence-associated genes (20 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 20 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of insulin secretion	3	32.9×	0.010	CACNA1C, ADCY8, PRKCA
Axon guidance	5	11.3×	0.010	RPS29, SDC2, CACNA1C, LHX2, PRKCA
Nervous system development	5	10.7×	0.010	RPS29, SDC2, CACNA1C, LHX2, PRKCA
Integration of energy metabolism	3	26.4×	0.015	CACNA1C, ADCY8, PRKCA
Developmental Biology	7	5.1×	0.017	RPS29, SDC2, CACNA1C, AKT3, LHX2, KAT2B, PRKCA
Regulation of beta-cell development	2	71.4×	0.019	AKT3, KAT2B
ESR-mediated signaling	3	19.2×	0.021	FKBP5, AKT3, KAT2B
Signaling by ROBO receptors	3	18.6×	0.021	RPS29, LHX2, PRKCA
GABA B receptor activation	2	54.4×	0.022	ADCY8, GABBR2
Syndecan interactions	2	42.3×	0.027	SDC2, PRKCA
Calmodulin induced events	2	38.1×	0.027	ADCY8, PRKCA
CaM pathway	2	38.1×	0.027	ADCY8, PRKCA
Ca-dependent events	2	36.8×	0.027	ADCY8, PRKCA
Rab regulation of trafficking	2	36.8×	0.027	TBC1D2, AKT3
Sensory Perception	3	14.3×	0.027	SDC2, LHX2, PRKCA
Intracellular signaling by second messengers	3	13.7×	0.027	ADCY8, AKT3, PRKCA
Signaling by ERBB2	2	34.6×	0.029	AKT3, PRKCA
FOXO-mediated transcription	2	33.6×	0.029	AKT3, KAT2B
G-protein mediated events	2	32.6×	0.029	ADCY8, PRKCA
DAG and IP3 signaling	2	31.7×	0.029	ADCY8, PRKCA
SARS-CoV-2 Infection	3	12.1×	0.029	RPS29, SDC2, AKT3
Opioid Signalling	2	26.6×	0.034	ADCY8, PRKCA
PLC beta mediated events	2	26.6×	0.034	ADCY8, PRKCA
EPHB-mediated forward signaling	2	26.6×	0.034	SDC2, GRIN1
Visual phototransduction	2	25.9×	0.034	SDC2, PRKCA
Disease	6	3.9×	0.038	RPS29, SDC2, SLC4A4, ADCY8, AKT3, KAT2B
G alpha (z) signalling events	2	23.3×	0.039	ADCY8, PRKCA
Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)	1	285.5×	0.041	SLC4A4
Signaling by VEGF	2	22.0×	0.041	AKT3, PRKCA
SARS-CoV Infections	3	8.3×	0.057	RPS29, SDC2, AKT3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 32 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
propylene metabolic process	1	526.6×	0.064	GRIN1
presynaptic signal transduction	1	526.6×	0.064	SIPA1L2
positive regulation of angiotensin-activated signaling pathway	1	526.6×	0.064	PRKCA
response to glycine	1	526.6×	0.064	GRIN1
activation of protein kinase A activity	1	263.3×	0.064	ADCY8
response to phorbol 13-acetate 12-myristate	1	263.3×	0.064	PRKCA
negative regulation of rRNA processing	1	263.3×	0.064	KAT2B
positive regulation of memory T cell activation	1	263.3×	0.064	CYRIB
positive regulation of dense core granule biogenesis	1	263.3×	0.064	PRKCA
N-terminal peptidyl-lysine acetylation	1	175.5×	0.064	KAT2B
oviduct epithelium development	1	175.5×	0.064	CSMD1
collateral sprouting in absence of injury	1	175.5×	0.064	COBL
calcium ion transmembrane transport via high voltage-gated calcium channel	1	175.5×	0.064	CACNA1C
dense core granule priming	1	175.5×	0.064	UNC13C
membrane depolarization during atrial cardiac muscle cell action potential	1	175.5×	0.064	CACNA1C
immune system development	1	131.7×	0.064	CACNA1C
mammary gland branching involved in pregnancy	1	131.7×	0.064	CSMD1
protein kinase C signaling	1	131.7×	0.064	PRKCA
cellular response to morphine	1	131.7×	0.064	ADCY8
negative regulation of mitochondrial membrane permeability involved in apoptotic process	1	131.7×	0.064	MTRNR2L5
positive regulation of transcription from RNA polymerase II promoter by glucose	1	105.3×	0.064	KAT2B
somite specification	1	105.3×	0.064	COBL
internal peptidyl-lysine acetylation	1	105.3×	0.064	KAT2B
negative regulation of synaptic plasticity	1	105.3×	0.064	UNC13C
positive regulation of adenylate cyclase activity	1	105.3×	0.064	CACNA1C
cellular response to staurosporine	1	105.3×	0.064	MTRNR2L5
membrane depolarization during AV node cell action potential	1	105.3×	0.064	CACNA1C
neuron-glial cell signaling	1	105.3×	0.064	GABBR2
positive regulation of artery morphogenesis	1	105.3×	0.064	AKT3
bone regeneration	1	105.3×	0.064	LGR6

Therapeutics

Drugs indicated for this disease

0 approved, 14 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aripiprazole	Phase 3 (in late-stage trials)
Brexpiprazole	Phase 3 (in late-stage trials)
Clonidine	Phase 3 (in late-stage trials)
Cyclobenzaprine	Phase 3 (in late-stage trials)
Cycloserine	Phase 3 (in late-stage trials)
Desipramine	Phase 3 (in late-stage trials)
Estradiol	Phase 3 (in late-stage trials)
Fluoxetine	Phase 3 (in late-stage trials)
Midomafetamine	Phase 3 (in late-stage trials)
Naltrexone	Phase 3 (in late-stage trials)
Paroxetine	Phase 3 (in late-stage trials)
Prazosin	Phase 3 (in late-stage trials)
Propranolol	Phase 3 (in late-stage trials)
Sertraline	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetylcysteine, Alprazolam, Atenolol, Balovaptan, Brexanolone, Buprenorphine, Cannabidiol, Cannabinol, Carvedilol, Daridorexant, Dextroamphetamine, Doxazosin, Dronabinol, Escitalopram, Ganaxolone, Glecaprevir, Iloperidone, Insulin Human, Ketamine, Lactose, Anhydrous, Levetiracetam, Levodopa, Losartan, Methylphenidate, Midazolam, Mifepristone, Modafinil, Nabiximols, Nitrogen, Nitrous Oxide, Oxygen, Oxytocin, Phenylephrine, Pibrentasvir, Prasterone, Pregnenolone Succinate, Psilocybin, Reboxetine, Risperidone, Ropivacaine, Serine, Sodium Chloride, Topiramate, Yohimbine.

Drug target analysis

Approved (phase 4): 7 · Phase ≥3: 8 · Phased (≥1): 9 · Undrugged: 26

Druggability breadth: 14 of 35 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
RPS29	GENTAMICIN SULFATE
CACNA1C	REMIFENTANIL
FKBP5	TACROLIMUS ANHYDROUS
AKT3	CAPIVASERTIB
GABBR2	BACLOFEN
GRIN1	DEXTROMETHORPHAN
PRKCA	INGENOL MEBUTATE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CACNA1C	85	4
GRIN1	39	4
PRKCA	39	4
AKT3	18	4
GABBR2	4	4
FKBP5	3	4
KAT2B	3	3
RPS29	2	4
ADCY8	1	2
SDC2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
GENTAMICIN SULFATE	4	RPS29
REMIFENTANIL	4	CACNA1C
BEPRIDIL	4	CACNA1C
CLOTRIMAZOLE	4	CACNA1C
PROPIVERINE	4	CACNA1C
DIBUCAINE	4	CACNA1C
IMIPRAMINE	4	CACNA1C
DULOXETINE	4	CACNA1C
QUINIDINE	4	CACNA1C
ESTRADIOL	4	CACNA1C
TOLTERODINE	4	CACNA1C
PIMOZIDE	4	CACNA1C
NIMODIPINE	4	CACNA1C
NICARDIPINE	4	CACNA1C
AMLODIPINE	4	CACNA1C
VARDENAFIL	4	CACNA1C
CLEMASTINE	4	CACNA1C
ISRADIPINE	4	CACNA1C
TERFENADINE	4	CACNA1C
NISOLDIPINE	4	CACNA1C
SOLIFENACIN	4	CACNA1C
PINAVERIUM	4	CACNA1C
SILDENAFIL	4	CACNA1C
NIFEDIPINE	4	CACNA1C
XANOMELINE	4	CACNA1C
DILTIAZEM	4	CACNA1C
PRENYLAMINE	4	CACNA1C
OLICERIDINE	4	CACNA1C
PROPRANOLOL	4	CACNA1C
ALVIMOPAN	4	CACNA1C

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PRKCA	1,148	Binding:1131, Functional:15, ADMET:2
AKT3	660	Binding:644, Functional:16
CACNA1C	575	Binding:319, Functional:211, Toxicity:26, ADMET:19
GRIN1	481	Binding:435, Functional:40, ADMET:5, Toxicity:1
KAT2B	217	Binding:217
RPS29	96	Binding:96
GABBR2	57	Binding:35, Functional:21, ADMET:1
FKBP5	38	Binding:38
ADCY8	31	Binding:28, Functional:2, ADMET:1
SDC2	7	Binding:7
TLL1	5	Binding:5
NDRG1	4	Binding:4
LGR6	1	Binding:1
CYRIB	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
AKT3	2.7.11.1	non-specific serine/threonine protein kinase
KAT2B	2.3.1.48	histone acetyltransferase
PRKCA	2.7.11.13	protein kinase C

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CACNA1C	575
AKT3	660
GRIN1	481
KAT2B	217
PRKCA	1,148

Pharmacogenomics

Cohort genes with a PharmGKB record: 35; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
GENTAMICIN SULFATE	4	RPS29
REMIFENTANIL	4	CACNA1C
BEPRIDIL	4	CACNA1C
CLOTRIMAZOLE	4	CACNA1C
PROPIVERINE	4	CACNA1C
DIBUCAINE	4	CACNA1C
IMIPRAMINE	4	CACNA1C
DULOXETINE	4	CACNA1C
QUINIDINE	4	CACNA1C
ESTRADIOL	4	CACNA1C
TOLTERODINE	4	CACNA1C
PIMOZIDE	4	CACNA1C
NIMODIPINE	4	CACNA1C
NICARDIPINE	4	CACNA1C
AMLODIPINE	4	CACNA1C
VARDENAFIL	4	CACNA1C
CLEMASTINE	4	CACNA1C
ISRADIPINE	4	CACNA1C
TERFENADINE	4	CACNA1C
NISOLDIPINE	4	CACNA1C
SOLIFENACIN	4	CACNA1C
PINAVERIUM	4	CACNA1C
SILDENAFIL	4	CACNA1C
NIFEDIPINE	4	CACNA1C
XANOMELINE	4	CACNA1C
DILTIAZEM	4	CACNA1C
PRENYLAMINE	4	CACNA1C
OLICERIDINE	4	CACNA1C
ALVIMOPAN	4	CACNA1C

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	7	RPS29, CACNA1C, FKBP5, AKT3, GABBR2, GRIN1, PRKCA
B	Phased (≥1) drug, not yet approved	2	ADCY8, KAT2B
C	Druggable family + PDB, no drug	3	TLL1, CSMD1, DPP6
D	Druggable family + AlphaFold only, no drug	1	LGR6
E	Difficult family or no structure, no drug	22	SDC2, SLC4A4, TRPS1, PTPRVP, UST, TBC1D2, POGK, COBL, UNC13C, PRTFDC1 (+12 more)

Undrugged target profiles

26 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SDC2	7	—
SLC4A4	0	—
TLL1	5	—
TRPS1	0	—
PTPRVP	0	—
CSMD1	0	—
UST	0	—
TBC1D2	0	—
POGK	0	—
LGR6	1	—
COBL	0	—
UNC13C	0	—
PRTFDC1	0	—
SIPA1L2	0	—
CYRIB	1	—
MEX3B	0	—
ANKRD55	0	—
TRMT9B	0	—
TECRL	0	—
ZMAT3	0	—
DPP6	0	—
MTRNR2L5	0	—
MIR3166	0	—
LHX2	0	—
NDRG1	4	—
OTOR	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,399.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	758
PHASE2	137
PHASE4	52
PHASE1	51
PHASE3	46
PHASE2/PHASE3	24
PHASE1/PHASE2	18
EARLY_PHASE1	14

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05391971	PHASE4	ACTIVE_NOT_RECRUITING	Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder
NCT06414356	PHASE4	RECRUITING	The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
NCT06788522	PHASE4	NOT_YET_RECRUITING	The Effects of Orexin Antagonism on Fear Extinction in PTSD
NCT06903819	PHASE4	RECRUITING	Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
NCT07192536	PHASE4	NOT_YET_RECRUITING	Accelerated Neuromodulation for Concurrent Post-Traumatic Stress Disorder (PTSD) & Chronic Pain in Veterans
NCT07382596	PHASE4	RECRUITING	Cervical Plexus Hydrodissection With D5W Versus NS for Treatment-Resistant PTSD
NCT00006489	PHASE4	COMPLETED	Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)
NCT00025740	PHASE4	COMPLETED	Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder
NCT00050804	PHASE4	COMPLETED	Evaluation of Stress Disorders
NCT00120250	PHASE4	COMPLETED	Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
NCT00134446	PHASE4	UNKNOWN	Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
NCT00158262	PHASE4	COMPLETED	Effect of Propranolol on Preventing Posttraumatic Stress Disorder
NCT00203385	PHASE4	TERMINATED	Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder
NCT00203463	PHASE4	COMPLETED	Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)
NCT00204737	PHASE4	COMPLETED	Short Course Glucocorticoid Treatment for PTSD
NCT00208130	PHASE4	COMPLETED	Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians
NCT00208182	PHASE4	COMPLETED	Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma
NCT00208208	PHASE4	COMPLETED	Geodon (Ziprasidone) for Posttraumatic Stress Disorder
NCT00237393	PHASE4	COMPLETED	Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT00302107	PHASE4	COMPLETED	A Placebo-Controlled Study of Mirtazapine for PTSD
NCT00330239	PHASE4	COMPLETED	Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
NCT00347269	PHASE4	COMPLETED	Primary Care Intervention Strategy for Anxiety Disorders
NCT00352469	PHASE4	COMPLETED	Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety
NCT00391430	PHASE4	TERMINATED	Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder
NCT00648375	PHASE4	TERMINATED	Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder
NCT00700999	PHASE4	COMPLETED	Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)
NCT00706173	PHASE4	WITHDRAWN	Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)
NCT00917397	PHASE4	COMPLETED	The Outcome of Treatment of Traumatised Refugees With Psychotherapy and/or Antidepressants
NCT01087736	PHASE4	COMPLETED	Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy
NCT01271244	PHASE4	COMPLETED	Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder
NCT01325168	PHASE4	COMPLETED	The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With Post Traumatic Stress Disorder (PTSD)
NCT01490697	PHASE4	COMPLETED	Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments
NCT01517711	PHASE4	COMPLETED	Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
NCT01569685	PHASE4	COMPLETED	The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy
NCT01681849	PHASE4	COMPLETED	Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder
NCT01715519	PHASE4	COMPLETED	Vilazodone for the Treatment of Posttraumatic Stress Disorder
NCT01965366	PHASE4	COMPLETED	Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD
NCT02199652	PHASE4	COMPLETED	Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)
NCT02213900	PHASE4	COMPLETED	Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
NCT02258828	PHASE4	COMPLETED	An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PRAZOSIN	4	15
PAROXETINE	4	14
PROPRANOLOL	4	8
SERTRALINE	4	8
QUETIAPINE	4	7
NALTREXONE	4	6
ZIPRASIDONE	4	6
CYCLOSERINE	4	5
BREXPIPRAZOLE	4	4
CANNABIDIOL	4	3
PERAMPANEL	4	3
TOPIRAMATE	4	3
VENLAFAXINE	4	3
BREXANOLONE	4	2
DIVALPROEX SODIUM	4	2
GLECAPREVIR	4	2
KETAMINE HYDROCHLORIDE	4	2
NIACIN	4	2
NITROUS OXIDE	4	2
PIMAVANSERIN	4	2
RILUZOLE	4	2
SUVOREXANT	4	2
ZONISAMIDE	4	2
ATOMOXETINE	4	1
ATOMOXETINE HYDROCHLORIDE	4	1
BUPRENORPHINE HYDROCHLORIDE	4	1
CARVEDILOL	4	1
CLONAZEPAM	4	1
CLONIDINE	4	1
CLONIDINE HYDROCHLORIDE	4	1